Q3 earnings roll on, FDA pushes rare disease, uniQure’s Huntington’s therapy reaches review

0:00-23:00

The majority of the large pharmas have now reported third quarter earnings—spoiler alert: Eli Lilly made more money than anyone expected. Plus, the FDA dropped another initiative aimed at accelerating rare disease treatments; HHS greenlights the compounding of six unapproved peptides; and uniQure’s embattled gene therapy for Huntington’s disease has finally been accepted for review.

Publisher

BioSpace

Published

November 4, 2026

Duration

23 min

Format

Podcast

Category

Issues · Science

Source

RSS feed

B

BioSpace

@biospace

#q3earningsroll #fdapushesrare #uniqureshuntingtonstherapy #lifesciences

The Nile